John Freund
Direktor/Vorstandsmitglied bei SI-BONE, INC.
Vermögen: 4 Mio $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michael Heffernan | M | 59 | 22 Jahre | |
Garen Bohlin | M | 76 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 18 Jahre |
Michael A. Pisetsky | M | 46 | 9 Jahre | |
Jeffrey Dunn | M | 69 | 16 Jahre | |
Jeryl Hilleman | F | 66 | 20 Jahre | |
Laura Francis | F | 57 | 9 Jahre | |
Gary Guthart | M | 58 | 28 Jahre | |
Joseph Ciaffoni | M | 53 | 7 Jahre | |
Leonade D. Jones | F | 76 |
American Funds Fundamental Investors
Smallcap World Fund
The Growth Fund of America
| - |
Shirley Kuhlmann | F | 40 | 6 Jahre | |
Jack D. Henion | M | - |
Advion BioSciences, Inc.
Advion BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Advion BioSciences, Inc. provides bioanalytical contract services to the pharmaceutical industry. Its clients include academic institutions, biotechnology, and pharmaceutical companies. Advion is the partner of choice for pharmaceutical, biotechnology, and research customers requiring scientific excellence in their bioanalytical services and microfluidic chemistry systems. Its deep scientific expertise drives a product and services portfolio characterized by exceptional data quality, flexibility, speed, and regulatory compliance. Advion's excellence in method development provides a tremendous advantage in establishing reliable bioanalytical assays in a timely and cost-effective manner. Its expertise in technology development provides more information, better synthesis and mass analysis, higher yields, and substantially greater throughput. The company was founded in 1993 and is located in Ithaca, NY. | 31 Jahre |
Jane Chung | F | 53 | 3 Jahre | |
William Newell | M | 66 | 15 Jahre | |
Joseph W. Powers | M | 65 | 15 Jahre | |
David N. Chernoff | M | - |
Crescendo Bioscience LLC
Crescendo Bioscience LLC Miscellaneous Commercial ServicesCommercial Services Crescendo Bioscience, Inc. develops and commercializes quantitative blood tests for rheumatoid arthritis and other autoimmune diseases. It develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. The company was founded by Mike B. Centola and Christopher L. Sutton in July 2002 and is headquartered in South San Francisco, CA. | - |
David Patteson | M | 69 |
Advion BioSciences, Inc.
Advion BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Advion BioSciences, Inc. provides bioanalytical contract services to the pharmaceutical industry. Its clients include academic institutions, biotechnology, and pharmaceutical companies. Advion is the partner of choice for pharmaceutical, biotechnology, and research customers requiring scientific excellence in their bioanalytical services and microfluidic chemistry systems. Its deep scientific expertise drives a product and services portfolio characterized by exceptional data quality, flexibility, speed, and regulatory compliance. Advion's excellence in method development provides a tremendous advantage in establishing reliable bioanalytical assays in a timely and cost-effective manner. Its expertise in technology development provides more information, better synthesis and mass analysis, higher yields, and substantially greater throughput. The company was founded in 1993 and is located in Ithaca, NY. | - |
Linda Griego | F | 76 |
The Growth Fund of America
American Funds Fundamental Investors
Smallcap World Fund
| - |
Dave Rosa Rosa | M | 56 | 28 Jahre | |
Richard G. Capen | M | 89 |
Smallcap World Fund
| 31 Jahre |
Jeff Bertolini | M | - | 2 Jahre | |
W. Carlton Reckling | M | 62 | 12 Jahre | |
Jon Wigginton | M | 62 | 4 Jahre | |
Nicki Vasquez | M | 61 | 9 Jahre | |
Mika Nishimura | F | 60 | 3 Jahre | |
Daniel Joseph Cher | M | - | 12 Jahre | |
Scott Dreyer | M | 52 | 6 Jahre | |
Neil McFarlane | M | 51 | 2 Jahre | |
Scott Sudduth | M | - | 6 Jahre | |
Anshul Maheshwari | M | 44 | 3 Jahre | |
Helen Loh | F | 60 | 3 Jahre | |
Nikolas F. Kerr | M | 53 | 8 Jahre | |
Lou Rassey | M | 50 |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | - |
Michael Blanchard | M | - | 10 Jahre | |
Rita Balice-Gordon | M | 63 | 4 Jahre | |
Michael P. Ember | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 7 Jahre |
Heidi Hunter | F | 66 | 3 Jahre | |
Myria Crawford | F | - |
Medivance, Inc.
Medivance, Inc. Medical SpecialtiesHealth Technology Medivance, Inc. develops, manufactures and markets therapeutic temperature management products. The company was founded in 1998 and is headquartered in Louisville, CO. | - |
Henry Heinsohn | M | - | - | |
Keith Valentine | M | 56 | 9 Jahre | |
Connie Matsui | F | 70 | 5 Jahre | |
James Panek | M | 71 | 4 Jahre | |
Gino Santini | M | 66 | 12 Jahre | |
Daniel Petree | M | 68 | - | |
Joseph Lobacki | M | 65 | 7 Jahre | |
Gregory Hinckley | M | 77 | 13 Jahre | |
Gwen Melincoff | M | 72 | 7 Jahre | |
Edward Albini | M | 66 | 11 Jahre | |
Linda Fitzpatrick | F | 67 | 16 Jahre | |
Ward S. McNally | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 17 Jahre |
Timothy Davis | M | 53 | 16 Jahre | |
Robyn Capobianco | M | - | 3 Jahre | |
John Fallon | M | 76 | 8 Jahre | |
Michael Dybbs | M | 49 | 6 Jahre | |
Joseph M. Kiely | M | - |
Advion BioSciences, Inc.
Advion BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Advion BioSciences, Inc. provides bioanalytical contract services to the pharmaceutical industry. Its clients include academic institutions, biotechnology, and pharmaceutical companies. Advion is the partner of choice for pharmaceutical, biotechnology, and research customers requiring scientific excellence in their bioanalytical services and microfluidic chemistry systems. Its deep scientific expertise drives a product and services portfolio characterized by exceptional data quality, flexibility, speed, and regulatory compliance. Advion's excellence in method development provides a tremendous advantage in establishing reliable bioanalytical assays in a timely and cost-effective manner. Its expertise in technology development provides more information, better synthesis and mass analysis, higher yields, and substantially greater throughput. The company was founded in 1993 and is located in Ithaca, NY. | - |
Gary A. Carson | M | - |
Medivance, Inc.
Medivance, Inc. Medical SpecialtiesHealth Technology Medivance, Inc. develops, manufactures and markets therapeutic temperature management products. The company was founded in 1998 and is headquartered in Louisville, CO. | - |
Eric M. Gordon | M | 78 |
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management LLC (Skyline Management) is a venture capital firm founded in 1997 by John Gordon Freund. The firm is headquartered in Palo Alto, California. | 22 Jahre |
Elena Hitraya | M | - |
Crescendo Bioscience LLC
Crescendo Bioscience LLC Miscellaneous Commercial ServicesCommercial Services Crescendo Bioscience, Inc. develops and commercializes quantitative blood tests for rheumatoid arthritis and other autoimmune diseases. It develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. The company was founded by Mike B. Centola and Christopher L. Sutton in July 2002 and is headquartered in South San Francisco, CA. | 9 Jahre |
Breaux B. Castleman | M | 83 |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 16 Jahre |
Ravi P Shah | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 8 Jahre |
Troy S. Wahlenmaier | M | - | 12 Jahre | |
Arun Padmanabhan | M | - | 7 Jahre | |
Carlos Lugo | M | - | - | |
David Pauling | M | - | - | |
Thomas Smith | M | 63 | 2 Jahre | |
Hans-Peter Gerber | M | - | 1 Jahre | |
Werner Rubas | M | - | 3 Jahre | |
Steve Shlensky | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | - |
Christopher James | M | - | 1 Jahre | |
Eric H. Sasso | M | - |
Crescendo Bioscience LLC
Crescendo Bioscience LLC Miscellaneous Commercial ServicesCommercial Services Crescendo Bioscience, Inc. develops and commercializes quantitative blood tests for rheumatoid arthritis and other autoimmune diseases. It develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. The company was founded by Mike B. Centola and Christopher L. Sutton in July 2002 and is headquartered in South San Francisco, CA. | 12 Jahre |
Scott A. Yerby | M | 56 | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Frederic Moll | M | 72 | 16 Jahre | |
Larry G. Edwards | M | 52 | 5 Jahre | |
Daniel T. Wallace | M | 57 | 6 Jahre | |
Guy L. de Chazal | M | 76 |
Morgan Stanley Venture Partners
Morgan Stanley Venture Partners Investment ManagersFinance Morgan Stanley Venture Partners (MSVP) is a venture capital firm subsidiary of Morgan Stanley Investment Management Merchant Banking, which is ultimately owned by Morgan Stanley (NYSE: MWD) founded in 1986.The firm is headquartered in New York.
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | 21 Jahre |
William Rieflin | M | 64 | 12 Jahre | |
Lonnie Smith | M | 79 | 23 Jahre | |
Wendell Wierenga | M | 76 | 16 Jahre | |
Robert G. Younge | M | 71 | 7 Jahre | |
Vincent Angotti | M | 56 | 8 Jahre | |
Ronald W. Barrett | M | 68 | 16 Jahre | |
Paul Brannelly | M | 51 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 11 Jahre |
Gary C. Restani | M | 77 | 3 Jahre | |
Mark A. Reiley | M | 74 | 11 Jahre | |
Steven van Dick | M | 69 | 5 Jahre | |
Lawrence G. Miller | M | 70 | 7 Jahre | |
Gianna M. Bosko | F | 54 | 10 Jahre | |
Daniel Janney | M | 58 | - | |
Guy MacDonald | M | 65 | 11 Jahre | |
Scott W. Borland | M | 53 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | - |
Russell C. Hirsch | M | 62 | 10 Jahre | |
Douglas Cole | M | 63 | 7 Jahre | |
Timothy Nelson | M | 60 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | 8 Jahre |
Ivan Delevic | M | 59 |
MAKO Surgical Corp.
MAKO Surgical Corp. Medical SpecialtiesHealth Technology MAKO Surgical Corp. is a medical device company, which develops and markets advanced robotic arm solution, joint specific applications for the knee, hip and orthopedic implants for orthopedic procedures. It also provides RIO robotic arm interactive orthopedic system, including a tactile robotic arm utilizing an integrated bone cutting instrument and a patient specific visualization component. The company was founded by Maurice R. Ferre and Rony A. Abovitz in November 2004 and is headquartered in Fort Lauderdale, FL. | 4 Jahre |
David M. Shaw | M | 57 | 6 Jahre | |
Eran Nadav | M | 55 | - | |
Peter Elliott | M | 64 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Alison B. Fleming | M | 49 | 19 Jahre | |
V. Lawlis | M | 72 | 16 Jahre | |
Richard Pops | M | 62 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Marlo Manning | F | - | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Freund
- Persönliches Netzwerk